Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Visible Genetics cooperates with Virology Networks:

This article was originally published in Clinica

Executive Summary

Visible Genetics and Utrecht, Netherlands-based Virology Networks have formed a joint venture, Visible Molecular Standards (VMS), to produce quality control and quantitative standards for identifying HIV, Hepatitis B and C, CMV and other infectious organisms. Visible Genetics, of Toronto, Canada, will contribute 35,000 shares and will finance the development of the joint venture. VMS will also set up a database of existing and new HIV genotypes, as well as their resistance to specific HIV drugs, in Europe and the US.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT082834

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel